NasdaqGM:MIRMBiotechs
Mirum Pharmaceuticals Expands Rare Liver Portfolio With Bluejay Hepatitis Delta Deal
Mirum Pharmaceuticals (NasdaqGM:MIRM) has completed its acquisition of Bluejay Therapeutics, adding a late stage hepatitis delta virus treatment to its pipeline.
The acquired asset carries Breakthrough Therapy and PRIME designations, highlighting regulatory focus on the underlying unmet medical need.
This transaction expands Mirum's rare liver disease franchise beyond its existing portfolio into a new viral liver disease indication.
For you as an investor, this deal brings Mirum further...